为改善晚期胃癌治疗现状，研究人员开展靶向 BCL XL 和 MCL 1 的研究，发现联合抑制可增强抗癌活性。 胃癌是全球第五大常见且致命的癌症，多数晚期患者预后差，现有治疗手段效果不佳。为了找到更有效的治疗策略，中国医学科学院 & 北京协和医学院的研究人员 ...

《自然·衰老》杂志发表的一项研究揭示了一种有前景的新药物候选物，可能有助于对抗代谢功能障碍相关脂肪性肝病（MASLD）。这种慢性肝病在圣安东尼奥社区中尤为常见，因为该地区肥胖和糖尿病的发病率较高。该病可能导致严重的并发症，如肝纤维化、肝硬化和肝癌，是一个重大的公共卫生挑战。

A recent study published on January 31, 2024, in Nature Aging introduces a potential new drug that could help. Scientists believe this drug can remove harmful “zombie” cells from the liver and slow ...

The groundbreaking study demonstrates drug candidate can safely and effectively target and eliminate senescent cells, also known as “zombie cells,” from the liver.

A study published in Nature Aging has revealed a promising new drug candidate that may help combat metabolic dysfunction-associated steatotic liver disease (MASLD), a chronic liver condition that ...

The BCL2 family of proteins, comprising both pro-apoptotic (BAX, BAK) and pro-survival (BCL2, BCL-XL, MCL1 and BCL-W) members, are pivotal players in this process. Protein–protein interactions ...

Most importantly, he found differential expression changes that always led to prosurvival adaptation of senescent cells mediated by BCL-XL, an anti-apoptotic protein that prevents the process of ...